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We hypothesized that some molecular pathways might interact to initiate the process of nervous tissue 
destruction, promoting cardiac autonomic neuropathy (CAN) in the course of diabetes type 1 (T1D). 
The study group consisted of 60 T1D patients (58.33% women/41.67% men), on standard therapy. The 
control group consisted of twenty healthy volunteers recruited in accordance with age, gender and 
body weight. The presence of CAN was documented by the Ewing test method (ProSciCard apparatus). 
A microarray data analysis was performed using Gene Spring version 13. The microarray results for 
selected genes were confirmed by real-time PCR (qRT-PCR), using specific TaqMan Gene Expression 
Assays. Plasma IL-6 content was measured by an enzyme-linked immunosorbent assay (ELISA). 
The p < 0.05 value was considered as statistically significant. The microarray analysis, confirmed by 
qRTPCR, showed significant up-regulation of autophagy, quantity of mitochondria, quality regulatory 
genes (mTOR, GABARAPL2) apoptosis, ER-stress and inflammation (NFKB1, IL1b, IL1R1, SOD1), in 
T1D when compared to the control group. A significantly higher IL-6 protein level was observed in 
T1D patients, in comparison to the control group. We concluded that the observed changes in gene 
expression and activation of intracellular pathways give a coherent picture of the important role 
of oxidative stress in inflammation and the activation of apoptosis in the pathomechanism of DM. 
The significance of the inflammatory process, confirmed by the increased level of the inflammation 
biomarker IL-6 in the pathomechanisms of CAN was shown even in patients with properly treated T1D.
The participation of different genes in the pathogenesis of type 1 diabetes T1D has been theoretically postu-
lated and accepted for a long time1. However, the genetic risk of T1D has only recently been analysed using 
genome-wide association studies, identifying over 60 T1D related susceptibility regions within the human 
genome, marked by single nucleotide polymorphisms2. This gene expression analysis revealed changes in 
genes related to inflammation (cytokines) and endoplasmic reticulum (ER) stress, leading to the activation of 
apoptosis3.
Neuropathy is considered one of the most common major complications of diabetes4. It is well established 
that hyperglycaemia induces oxidative stress in cells such as neurons and immune cells, resulting in the activa-
tion of local inflammation and autophagy/apoptosis mechanisms which may be responsible for the pathogenesis 
and progression of diabetic neuropathy4,5. Cardiac autonomic neuropathy (CAN), caused by the destruction of 
autonomic nerve fibres in the heart and blood vessels, results in abnormalities in heart rate control and vascular 
dynamics. CAN is a significant cause of morbidity and mortality, associated with a high risk of cardiac arrhyth-
mias and sudden death in DM patients6. It is well known that CAN is an important predictor of cardiovascular 
events in the diabetic population of patients7.
Multicentre clinical trials confirmed the stimulation of chronic diabetes complications through the deteri-
oration of metabolic control8,9. The non-enzymatic glycation of proteins (AGEs) alter intracellular signalling 
through proinflammatory cytokines such as IL-6, TNF-α and free radicals, which further propagate diabetic 
complications10. It should be noted however, that the mechanism of this chronic complication is not completely 
understood. It is believed to partially arise from deficient nerve regeneration due to concomitant inflammatory 
processes involving the induction of transmembrane glycoprotein 130 (gp130), which is important for IL-6 signal 
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transduction11. The induction of gp130 family of cytokines parallel axonal injury, in the experimentally induced 
diabetic mice, significantly decreased axonal regeneration12.
This study’s goal is to follow, by microarray, the possible alteration of blood cell molecular pathways which 
may be altered to initiate the process of nervous tissue destruction in the course of T1D.
Material and Methods
Patients were selected from those attending the diabetic clinic at JUMC Department of Metabolic Disorders. The 
study group consisted of 60 patients with T1D, confirmed with a positive anti-GAD test result. These patients 
were treated with a standard therapeutic regimen: multiple daily injections (MDI) or continuous subcutaneous 
insulin infusions (CSII). The patients were randomized into two subgroups depending on the presence or absence 
of symptoms of autonomic neuropathy.
The control group (n = 20) consisted of healthy non-obese volunteers recruited in accordance to age, gen-
der and body weight. The exclusion criteria for all participants were: age under 20 and above 65 years; met-
abolic syndrome, cardiovascular diseases, cancer, chronic inflammation; severe liver or kidney failure, iron 
deficiency anaemia; pregnancy, breast feeding, hormone replacement therapy; anticoagulant treatment; usage of 
anti-inflammatory drugs and lack of the patient’s written consent to participate in the study. The study protocol 
was approved by the Jagiellonian University Bioethical Committee and was in accordance with the Declaration of 
Helsinki. Informed consent was obtained from all individual participants included in the study.
Evaluation of autonomic neuropathy (CAN). The presence of CAN was based on the outcome of the 
reference method using the ProSciCard apparatus (Ewing test)13. The severity of the cardiovascular neuropathy 
in the investigated group was determined by the number of abnormal results (from 3 up to 5) of Ewing test and 
pathological blood pressure variability [the guidelines for 2018 year of Polish Society of Diabetes]13.
Fasting venous blood was sampled from each participant for further tests. Part of the sample was sent for a 
routine laboratory diagnostic test, and another part was immediately centrifuged for serum isolation, and then 
transferred into sterile eppendorfs and stored at −20 °C. Whole blood samples were collected for mRNA isolation 
using PAXgene Blood RNA Tubes (Becton Dickinson) for material stabilization and transport. Each study par-
ticipant underwent laboratory tests assessing the level of metabolic control, including: HbA1c level, lipidogram, 
renal markers, liver function tests and TSH levels. Biochemical tests were performed at the main Laboratory 
Diagnostics Department in the University Hospital, in accordance with standard procedures.
RNA isolation. Purification of total RNA from human whole blood was performed using the PAXgene Blood 
RNA Kit, following producer protocol. The RNA quality was analysed using the Tapestation 2200 instrument 
(Agilent, USA) and quantified by spectrophotometry on the NanoDrop (Thermo Fisher Scientific, Wilmington, 
DE, USA).
Microarray. The RNA quality testing resulted in the removal of samples not fulfilling the minimum quality 
criteria. Amplification of RNA was performed using the Illumina Amplification kit (Ambion, USA). The Quick 
Amp labelling kit was used for total RNA labelling according to the manufacturer’s protocol. Hybridization of 
biotin-labelled cRNA to an Illumina chip was performed according to the manufacturer protocol. Arrays were 
scanned on a HiScan scanner (Illumina, USA).
Microarrays statistical analysis. Microarray was used as a screening method. It was used for selected 
samples: T1DM without CAN (Ewing test result 1–2), T1DM + CAN group (in Ewing test 4–5 abnormal results). 
A microarray data analysis was performed using Gene Spring version 13 (Agilent Technologies, Santa Clara, 
USA). To identify differentially expressed genes, we applied a quartile normalization with background correc-
tion to identify the median of all samples for the Illumina chip. Separation of different groups for analysis was 
carried out by dividing patients into two categories: those with diabetes mellitus without neuropathy (T1D) and 
those with neuropathy (T1D + CAN); PCA (Principal component analysis). PCA was used to discriminate three 
different groups: T1D, T1D + CAN and ctrl. 3D view of the PCA plot where the three axis are the three principal 
components (first three by default). Component 1 (X-axis) 57,37%, Component 2 (Y-axis) 4,58%, Component 3 
3,47%. Based on the PCA plot analysis, some of the outlier results were excluded from further microarray analysis 
(Fig. 1), in order to achieve the most homogeneous groups. The outliers on microarray data, in the majority, there 
were samples of patients that had other factors attributing to the deviations like other chronic complications. 
From the performed microarray hybridization samples with T1D, only 13 (from 24), T1D + CAN 13 (from 20) 
and 4 control (from 5) samples were used for further analysis. A smaller number of samples for further analysis 
were chosen due to the very restrictive clinical characterisation used for patients with the strongest manifestation 
of CAN (T1D + CAN), in Ewing test 5 abnormal results, and patients without any complications as the T1D 
group (Fig. 2). The one-way ANOVA with post-hoc Tukey test revealed 6737 significantly regulated genes in 
T1D + CAN vs. control group, T1D vs. control analysis showed 6550 items; while T1D + CAN vs. T1D covered 
725 significantly regulated genes. Among this number, 44 significantly regulated genes, overlapped in all inves-
tigated groups. The Venn diagram illustrates the differentially expressed genes identified between each pair of 
group comparison (Fig. 3). A normalized signal was used for the fold of change (FC) calculation. FC was calcu-
lated in relation to the control group (Ctrl), and T1D + CAN vs T1D and used as the expression level. The list of 
significantly regulated transcripts with p < 0.05 was generated using statistical filtering (one-way ANOVA, as well 
as Tukey post-hoc test with multiple test correction FDR) (data presented in supplementary materials, Table S1).
In the microarray data analysis, in relation to the biological pathways, the Gene Set Expression Comparison 
(GSEC) was used for examination of significantly regulated gene sets in pathways (Kegg pathways list) among 
pre-defined classes of arrays. The list of significantly regulated transcripts with p < 0.05 (FDR) was generated 
using univariate two-sample T-test (with random variance model). Tests used to find significant gene sets were: 
3Scientific RepoRtS |         (2020) 10:5554  | https://doi.org/10.1038/s41598-020-62498-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
LS (least squares)/KS (Kolmogorov-Smirnov) permutation test and Efron-Tibshirani’s GSA max/mean test. The 
threshold of determining significant gene sets was 0.05.
Real-time PCR. The microarray results for selected genes were confirmed by real-time PCR. The selec-
tion of genes for further analysis by RT-PCR was based on the potentially interesting biological pathways that 
Figure 1. PCA plot analysis of microarray results after the exclusion of outlying test results. The group of 
diabetic patients without (T1DM) and with cardiac autonomic neuropathy (T1D + CAN), as well as the control 
group (Ctr).
Figure 2. The workflow chart showing the numbers of subjects enrolled in the study; included in the study; and 
finally included in microarray and qPCR analyses.
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demonstrated the significantly regulated genes in the Tukey post-hoc test. A real-time PCR analysis was per-
formed on the expanded research group on the basis of the results of the ProSciCard study. 30 CAN candi-
dates with expressed genes (4–5 pathological tests) and 30 T1D of patients with a normal Ewing test result were 
selected. In addition, 20 healthy people were analysed as a control group (Ctrl). Expression of 18SrRNA was used 
as a reference gene (Applied Biosystems). One μg of total RNA was reverse transcribed using the reverse tran-
scription kit (High Capacity cDNA Reverse Transcription Kit Thermo Fisher Scientific) with random and oligo 
dT primers. Subsequently, cDNA was used for real-time PCR. A quantitative real-time polymerase chain reaction 
(qPCR) was performed using specific TaqMan Gene Expression Assays with a pair of specific PCR primers and a 
TaqMan probe labelled with FAM (Thermo Fisher Scientific). An amplification was performed using the contin-
uous fluorescence detection 7900 HT Fast Real Time PCR system (Thermo Fisher Scientific). The expression ratio 
of the target mRNA was normalized to the level of 18 s RNA and compared with the Ctrl and DM + CAN. The 
data were analysed using the ΔΔCT method and presented as a mean ± standard deviation. Group differences 
were analysed using a Student T-test. All analyses were performed using Data Assist v3.01. A p < 0.05 value was 
considered statistically significant.
IL-6 level estimation. The plasma IL‐6 level was determined using an enzyme-linked immunosorbent assay 
ELISA (R&D Systems Europe, Ltd, Abingdon, United Kingdom), according to standard protocol. Each sample 
was performed in duplicates. Within‐ and between‐run imprecision coefficient of variations(CVs) were at level 
6% and 7%. The data was presented as mean ± standard deviation. The difference between groups was analysed 
using a Student T-test. The analysis was performed using Statistica (StatSoft). A p < 0.05 was considered statisti-
cally significant. The decision to choose IL-6 protein for further analysis was based on authors’ previous observa-
tion, published in Atherosclerosis journal14. The previous analysis of proteins involved in inflammatory process, in 
the similar cohort of T1DM patients, gave us arguments to choose IL-6.
Ethical approval. All procedures performed in this study involving human participants were in accordance 
with the ethical standards of the Jagiellonian University Bioethical Committee and with the 1964 Helsinki decla-
ration and its later amendments or comparable ethical standards.
Results
A total of 60 people were qualified for further analysis, including 58.33% women and 41.67% men. The median 
duration of diabetes was 15 years. Of the examined patients, 58.4% were using MDI, with the rest using CSII. The 
daily insulin dose (41U vs. 44U) in both groups did not differ significantly. They were examined for the presence 
of other chronic complications, particularly peripheral neuropathy and retinopathy. None of the patients had 
advanced painful, peripheral, or severe neuropathy, nor did they demonstrate proliferative retinopathy. The clini-
cal/biochemical characteristics of the analysed groups was presented in the Table 1 (Table 1). The detailed clinical 
characteristic of investigated group was presented in our previous paper15.
Based on the microarray results in the pathway analysis, we focused on genes related to ER-stress, apopto-
sis, glucose metabolism and inflammation. The genes were categorized according to the Gene Ontology (GO) 
database using GeneSpring 13 (supplementary materials, Table S1). The entire group of T1D patients demon-
strated up-regulation of genes related to ER-stress activation (ATF6, PRDX6, GCLC, TXNRD1, SOD2), as well 
as down-regulation of genes coding proteins involved in glucose transport into the cells (SLC2A11) parallel 
with glycolysis activation, and up-regulation of carnitine production (SETDB1, DOT1L, SETD2, ALDH9A1). 
Figure 3. The Venn diagram illustrating the differentially expressed genes identified between each pair of group 
comparison. The data illustrates significantly regulated genes after one-way ANOVA with post-hoc Tukey test 
(prepared using GeneSpring tools). The group of diabetic patients without (T1DM) and with cardiac autonomic 
neuropathy (T1D + CAN), the control group (Ctr).
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Additionally, we observed inhibition of alternative pathways that use glucose as a substrate, such as the one 
involved in the synthesis of glycosaminoglycans (B3GAT1). Up-regulation of genes related to proteasome for-
mation was also observed (subunit of proteasome 26S and proteasome 20 complex). Activated ER-stress (con-
firmed by up-regulation of ATF6) provides evidence for the activation of autophagy or apoptosis. These patients 
additionally demonstrated an up-regulation of the expression of genes related to autophagosome formation (e.g. 
ATG3, ULK1, BECN1, DNAJB1, SQSTM1) but FRAP1, ATG10, GABARAPL2, while proteolytic enzymes in the 
lysosomes (catepsins) were down-regulated. Additionally, we discovered down-regulation of the expression of 
the gene coding the subunit of the protein that builds the H+-ATPase lysosome membrane complex, which is 
designed to activate lysosomal hydrolytic enzymes through lowering the pH of the local environment. The expres-
sion of genes associated with apoptosis was also up-regulated (caspases, TNF family factors and their receptors). 
We observed an increased gene expression for NFKB family factors in T1D; which activates the production of 
pro-apoptotic proteins from the BCL2 family (supplementary materials, Table S1). We were not able to find sig-
nificant differences in the gene expression profile between the two groups of T1D patients with and without CAN. 
Results related to this analysis were presented in Table S1 (supplementary materials, Table S1).
Furthermore, using the microarray results analysis comparing T1D patients with the healthy control, we 
observed the activation of genes encoding enzymes involved in DNA repair, as well as the inhibition of expression 
of proteins of complexes I and III, which provide evidence for the impairment of mitochondrial function.
The results of microarray analysis showed significantly regulated genes related to autophagy (GABARAPL2, 
FRAP1, CTSL, CTSW), apoptosis (BCL2L13), inflammation (IL1b, IL1R1, NFKB1), DNA repair (APEX1, ERCC3, 
ERCC5) and antioxidant enzymes (PRDX1, SOD1), which was verified and confirmed by qRT-PCR (Fig. 4).
The gene expression analysis demonstrated the activation of pathways associated with the inflammatory pro-
cess. In order to confirm this observation, the plasma level of IL-6 protein was determined. IL-6 is well-known and 
reliable inflammatory biomarker, and the choice was dictated by our previous observations in T1DM patients14. We 
observed a significantly higher concentration of this cytokine in the group of T1D + CAN patients, both compared 
to the group of T1D patients without CAN (p = 0.0074) as well as the control group (p = 0.0021) (Fig. 5).
Discussion
Despite many years searching for the pathomechanism of the development of chronic T1D complications, includ-
ing CAN, we still do not have a complete picture. The presented work is one of the first related to this field publi-
cations focusing on pathways involved in CAN development in T1D patients, undertaken by analysing blood cell 
gene expression measured by microarray. In our study, we presented results from a homogeneous T1D group of 
patients, which minimizes the number of variables interfering with the analysis.
PARAMETER (±SD) T1D (n = 30) T1D + NSN (n = 30) control (n = 20) p
Sex (F/M) % 69/31 60/40 70/30 NA
Age (years) 19.6 ± 5.8 33 ± 17.9 34.4 ± 19.3 NA
Insulin use /day (U) 45 ± 11.4 48 ± 7.2 0 p < 0.0001 (#)
BMI (kg/m2) 21.4 ± 2.9 23.1 ± 4.3 23.6 ± 3.7 NA
HbA1c (%) 7.78 ± 1.39 8.62 ± 1.72 5.21 ± 1.72 p < 0.01 (* and #)
Ckr < 60 ml/min, n (%) 1 (3.3) 3 (10) 0 p < 0.05 (* and #)
Table 1. Clinical characteristics of study participants: T1D patients with and without CAN, as well as control 
group. Clinical characteristics of study participants with T1D (n = 60). Ckr –Clearance of Creatinine. *Significant 
result (p < 0.05) for T1D vs T1D + NSN. #Significant result (p < 0.05) for all patients with T1DM vs control.
Figure 4. Changes in gene expression of selected genes related to autophagy (GABARAPL2, FRAP1, CTSL, 
CTSW), apoptosis (BCL2L13), inflammation (IL1b, IL1R1, NFKB1), DNA repair (APEX1, ERCC3, ERCC5) 
and antioxidant enzymes (PRDX1, SOD1) in patients with diabetes mellitus. Data are presented as mean ± SD; 
(*p < 0.05; #p > 0.05 but <0.06−).
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The analysis of gene expression in the investigated group of T1D patients documented the up-regulation of 
genes related to ER-stress. This observation is in accordance with the in vitro study on Schwann cells, where the 
variation of glucose concentration significantly stimulated ER-stress gene expression in the investigated model16. 
Additionally, the activation of enzyme expression involved in DNA repair, with concomitant inhibition of the 
expression of components of mitochondrial complexes I and III, pointed to disturbed mitochondrial function, 
confirming the intensification of oxidative stress17. This observation is in accordance with the reported outcome 
of the experimental animal model study, where mitochondrial dysfunction in cerebellar Purkinje neurons was 
associated with motor coordination deficits in STZ-diabetic rats, suggesting a novel cellular mechanism of dia-
betic neuropathy18. Various forms of mitochondrial dysfunction such as the inhibition of the respiratory chain, a 
decrease in ATP generation, and the loss of mitochondrial membrane potential have been previously confirmed 
in neurodegenerative diseases19. Sifuentes-Franco et al. documented the role of oxidative stress, mitochondrial 
dysfunction and impaired autophagy in diabetic polyneuropathy, suggesting that oxidative stress plays a predom-
inant role in neuronal death in DM20. Other prospective and clinical analyses of inflammatory biomarkers and 
distal sensorimotor polyneuropathy pointed to a complex cross-talk between innate and adaptive immunity in 
the pathogenesis of this disease21.
In diabetes, disturbances in blood glucose control cause non-enzymatic protein modification and increased 
protein degradation by proteasomes and ROS production5. In the studied group of patients, we observed 
increased expression of genes of proteins involved in these events. ER-stress activation through ATF6 expression 
points to the activation of autophagy or apoptosis22,23. The increased expression of enzymes with antioxidant 
potential, also provide evidence for the activation of protective mechanisms induced by an abnormal amount of 
ROS generated within the cells. Activation of gene expression associated with the formation of autophagosomes 
(LAMP1, RAB24, GUSB) is also consistent with this phenomenon24. It should be noted however, that patients 
despite the increased formation of autophagosomes in T1D, the process of removing damaged proteins through 
autophagy is inefficient due to the inhibition of lysosomal hydrolysis25. This observation is in compliance with 
our results, as we have observed the down-regulation of genes coding lysosomal proteases (catepsins). It has been 
shown that hyperglycaemia in neurons leads to the activation of multiple biochemical and molecular pathways, 
including protein kinase (PKCs) signalling, which may be crucial for the pathogenesis and progression of diabetic 
neuropathy4.
Additionally, we observed down-regulation of gene expression coding the subunit of protein that builds the 
H+-ATPase lysosome membrane complex, which, activate lysosomal hydrolytic enzymes through lowering the 
pH of the environment. It may be a potential mechanism of the functional disruption of autophagy, which leads 
to the activation of cellular apoptosis under the cellular stress in T1D patients26. The protective effect of activated 
autophagy against cellular death in glucose/ROS-mediated apoptosis has been previously recorded27. In our study, 
we observed the up-regulation of the expression of the TNF family and their receptors and the NFKB family, as 
well as an increase in the expression of caspases genes. These events are documented to be linked with increased 
biosynthesis of pro-apoptotic proteins from the BCL2 family28.
In our T1D patients, we detected a decreased expression of glucose transporters involved in the activation of 
glycolysis and pathways in which other metabolic substrates could be used as an energy source, such as amino 
acids and fatty acids. This was evidenced by the increased expression of enzymes participating in carnitine syn-
thesis for the more efficient transport of fatty acids to the mitochondrion. In contrast, we observed inhibition of 
pathways that use glucose for other purposes, such as the synthesis of glycosaminoglycans. These observations 
concur with the outcome of another study, where gene expression analysis in pancreatic islets from T1D patients 
showed not only up-regulation of genes involved in cell death, but significant inhibition of glucose transport as 
well3.
We must stress that we were did not find a significant difference in the measured gene expression profile 
between sub-groups of T1D patients. The lack of significant differences in gene expression between these groups 
may be the result of a uniform and intensive model of treatment for these patients, in the form of functional insu-
lin therapy. Good metabolic control, high homogeneity of both T1D groups with and without neuropathy, and 
relative insulin demand could be reasons for the lack of significant differences in our analysis. On the other hand, 
despite the optimization of treatment, we found significant differences in genes belonging to various pathways 
Figure 5. The level of proinflammatory cytokine (IL-6) in the group of diabetic patients without (T1DM) and 
with cardiac autonomic neuropathy (T1D + CAN), both compared to the control group (Ctr). (*p = 0.0074 
T1D + CAN vs T1D; **p = 0.0021 T1D + CAN vs Ctr).
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between T1D patients and the healthy control group. This proves that a good clinical control is not successful in 
suppressing the pathogenic processes leading to the development of diabetes, its progression and the development 
of chronic complications such as CAN.
The significantly higher gene expression associated with the inflammatory process was expressed in both 
sub-groups of T1D patients. It should be noted that in T1D + CAN patients demonstrated a significantly higher 
blood level of IL-6 in comparison to the other analysed groups. This persisted despite intensive insulin therapy 
with satisfactory metabolic control and strongly argue for the role of inflammatory processes in the development 
of T1D complications. In the selection of patients for the study, homogeneity of the group was ensured regarding 
their clinical status and the severity of chronic complications, thus reducing the influence of other factors on the 
examined biomarkers. The lack of differences in IL-6 gene expression between T1D + CAN and T1D may point 
to the role of post-translational processes in this mechanism. Another explanation could be that the presence 
of autonomic neuropathy might result from local, tissue-specific disturbances in metabolic control. It has been 
shown that both hyper and hypoglycaemic episodes have pro-inflammatory potential in T1D patients14. Previous 
clinical trials have confirmed the association of inflammatory biomarkers with CAN in patients with recently 
diagnosed T2DM. However, there was no clear association between CAN and IL-6 in this group of patients29. A 
considerable weakness of this study is the limited number of the participants. However, it should be noted that the 
homogeneity of the groups involving the type of diabetes, race, treatment model, metabolic control and comor-
bidities helped mitigate many confounding effects. Additionally, the measured changes in gene expression were 
analysed in the genome of peripheral blood cells. The neuropathy may result from local inflammation related to 
neuron cell specific regulation of gene expression due to metabolic, ischemic, and/or inflammatory processes. 
In the absence of clinical input for cardiac interventions and for bioethical reasons, a cardiac conduction system 
biopsy was not possible in our study model.
Our observations on the changes in gene expression and the activation of intracellular pathways, confirmed by 
the level of inflammatory proteins, provide a coherent picture of the potential role of aggravated oxidative stress 
inflammation and the activation of apoptosis in pathomechanisms of CAN in patients with properly treated T1D. 
We believe that it is crucial to concentrate on the study of specific changes in neuronal tissue in future studies of 
the pathomechanisms of CAN in type 1 diabetes patients.
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